| Primary information |
|---|
| sequence ID | Seq_6976 |
| Peptide sequence | SEETKENEGFTVTAEGK |
| CancerPDF_ID | CancerPDF_ID942, CancerPDF_ID1468, CancerPDF_ID2705, CancerPDF_ID8556, CancerPDF_ID9605, CancerPDF_ID12169, |
| PMID | 19795908,21136997,21136997,23667664,21533267,26992070 |
| Protein Name | Complement C3,Complement C3,Complement C3,Complement C3f,Complement C3,Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN |
| Fluid | Plasma,Serum,Plasma,Serum,Serum,Serum |
| M/Z | "928.42, 619.28",1854.84832,1854.8483,1854.85,619.27,1854.8483 |
| Charge | "2, 3",1,1,1,3,NA |
| Mass (in Da) | NA,NA,NA,1856.94,NA,1855.854099 |
| fdr | NA,NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS,MALDI-TOF,LC-MS,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC-MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,NA,NA,NA,1.49,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID942, CancerPDF_ID1468, CancerPDF_ID2705, CancerPDF_ID8556, CancerPDF_ID9605, CancerPDF_ID12169, |
| p-Value | NA,NA,NA,NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT,SEQUEST and Maxquant |
| Length | 17,17,17,17,17,17 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Melanoma |
| Database | NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA |
| Number of Patients | "42 normal, 28 patients",30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
| Regulation | NA,NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 6 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." |
| Validation | NA,Leave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,na |
| Sensitivity | NA,NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |